<DOC>
	<DOCNO>NCT01350388</DOCNO>
	<brief_summary>Hyperuricemia emerge risk factor development diabetes metabolic syndrome . Recently , show in-vitro cell culture experiment hyperuricemia induces redox-dependent signal oxidative stress adipocytes . By target level uric acid febuxostat hypothesize level oxidative stress adipose tissue ( obtain fat biopsy ) decrease . Primary aim study determine whether febuxostat therapy overweight obese , diabetic patient stage 3 Chronic Kidney Disease ( CKD ) high serum uric acid level 1. affect adipose tissue concentration thiobarbituric acid reactive substance ( TBARS ) , marker oxidative stress 2. affect adipose tissue expression concentration adiponectin ; 3. affect urinary concentration transform growth factor ( TGF ) - B1 .</brief_summary>
	<brief_title>Effects Febuxostat Adipokines Kidney Disease Diabetic Chronic Kidney Disease</brief_title>
	<detailed_description>Hyperuricemia highly prevalent US population commonly cluster obesity metabolic syndrome . It remain controversial whether reflect epiphenomenon connotes causal role hyperuricemia metabolic syndrome . If indeed hyperuricemia play causal role metabolic syndrome , would expect hyperuricemia impact molecular signal mediate effect adiposity inflammation insulin resistance . Adipokines , protein hormone produce adipocytes , serve signal effect adipocytes insulin resistance , dyslipidemia , hypertension , inflammation atherosclerosis . Adipokines include tumor necrosis factor-α ( TNF-α ) , interleukin-6 ( IL-6 ) , plasminogen activator inhibitor ( PAI-1 ) , leptin , angiotensinogen adiponectin . In obesity , production TNF-α , IL-6 , PAI-1 , leptin angiotensinogen increase whereas production adiponectin decrease . Increased expression pro-inflammatory TNF-α IL-6 decreased expression anti-inflammatory adiponectin adipocytes result insulin resistance inflammation . As oxidative stress adipose tissue consider play critical role dysregulation adipokines production obesity hyperuricemia induces oxidative stress adipocytes , hypothesize hyperuricemia alters adipose tissue production adipokines ; therefore , febuxostat therapy decrease hyperuricemia thereby , beneficial effect adipokine production adipose tissue ; favorable effect adipokine production febuxostat therapy result decrease plasma level marker inflammation ; result , urinary marker kidney disease improve . Chronic Kidney Disease ( CKD ) patient type 2 diabetes study population high prevalence hyperuricemia likely represent target population might benefit reduction uric acid level . This placebo-controlled , double-blinded , randomize control trial examine effect uric acid lower oral febuxostat adipokines marker inflammation .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>Age &gt; 18 year BMI &gt; 25 kg/m2 type 2 diabetes serum uric acid ≥ 5.5 mg/dl men ≥ 4.6 mg/dl woman eGFR 3060 mL/min/1.73m2 History gout concurrent use azathioprine , mercaptopurine , theophylline , allopurinol , thiazolidinediones warfarin concurrent use metformin current antibiotic therapy pregnant woman prisoner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Febuxostat</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Hyperuricemia</keyword>
</DOC>